Research publications | Alfred Health

Reply to E. Hindié

Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, van Akkooi ACJ, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suciu S, Robert C

(2021), J Clin Oncol, 39(8), 944-6

DOI: 10.1200/JCO.20.03463

Reduced melanoma referrals during COVID-19 lockdown

Berry W, Tan K, Haydon A, Shackleton M, Mar VJ

(2021), Aust J Gen Pract, 50,

DOI: 10.31128/AJGP-COVID-45

Lifetime alcohol intake, drinking patterns over time and risk of stomach cancer: A pooled analysis of data from two prospective cohort studies

Jayasekara H, MacInnis RJ, Lujan-Barroso L, Mayen-Chacon AL, Cross AJ, Wallner B, Palli D, Ricceri F, Pala V, Panico S, Tumino R, Kühn T, Kaaks R, Tsilidis K, Sánchez MJ, Amiano P, Ardanaz E, Chirlaque López MD, Merino S, Rothwell JA, Boutron-Ruault MC, Severi G, Sternby H, Sonestedt E, Bueno-de-Mesquita B, Boeing H, Travis R, Sandanger TM, Trichopoulou A, Karakatsani A, Peppa E, Tjønneland A, Yang Y, Hodge AM, Mitchell H, Haydon A, Room R, Hopper JL, Weiderpass E, Gunter MJ, Riboli E, Giles GG, Milne RL, Agudo A, English DR, Ferrari P

(2021), Int J Cancer, 148(11), 2579-73

DOI: 10.1002/ijc.33504

Findings and Resolution of Melanoma Perineural Spread Along the Greater Auricular Nerve on FDG PET/CT and MRI

Nguyen J, Barber TW, Cameron R, Haydon A, Mar V

(2021), Clin Nucl Med, 46(6), e329-31

DOI: 10.1097/RLU.0000000000003534

Impact of Radiotherapy on the Efficacy and Toxicity of anti-PD-1 Inhibitors in Metastatic NSCLC

Samuel E, Lie G, Balasubramanian A, Hiong A, So Y, Voskoboynik M, Moore M, Shackleton M, Haydon A, John T, Mitchell PLR, Markman B, Briggs P, Parakh S

(2021), Clin Lung Cancer, 22(3), e425-30

DOI: 10.1016/j.cllc.2020.06.001

The acceleration of ageing in older patients with cancer

Muhandiramge J, Orchard S, Haydon A, Zalcberg J

(2021), J Geriatr Oncol, 12(3), 343-51

DOI: 10.1016/j.jgo.2020.09.010

Combined ipilimumab and nivolumab first-line and after BRAF-targeted therapy in advanced melanoma

Mason R, Dearden HC, Nguyen B, Soon JA, Smith JL, Randhawa M, Mant A, Warburton L, Lo S, Meniawy T, Guminski A, Parente P, Ali S, Haydon A, Long GV, Carlino MS, Millward M, Atkinson VG, Menzies AM

(2020), PIGM CELL MELANOMA R, 33(2), 358-65

DOI: 10.1111/pcmr.12831

Association Between Immune-Related Adverse Events and Recurrence-Free Survival Among Patients With Stage III Melanoma Randomized to Receive Pembrolizumab or Placebo: A Secondary Analysis of a Randomized Clinical Trial

Eggermont AMM, Kicinski M, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, Krepler C, Ibrahim N, Marreaud S, van Akkooi A, Robert C, Suciu S

(2020), JAMA Oncol, 6(4), 519-27

DOI: 10.1001/jamaoncol.2019.5570

Phase I, Open-Label, Dose-Escalation/Dose-Expansion Study of Lifirafenib (BGB-283), an RAF Family Kinase Inhibitor, in Patients With Solid Tumors

Desai J, Gan H, Barrow C, Jameson M, Atkinson V, Haydon A, Millward M, Begbie S, Brown M, Markman B, Patterson W, Hill A, Horvath L, Nagrial A, Richardson G, Jackson C, Friedlander M, Parente P, Tran B, Wang L, Chen Y, Tang Z, Huang W, Wu J, Zeng D, Luo L, Solomon B

(2020), J Clin Oncol, 38(19), 2140-50

DOI: 10.1200/JCO.19.02654

Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy

Owen CN, Shoushtari AN, Chauhan D, Palmieri DJ, Lee B, Rohaan MW, Mangana J, Atkinson V, Zaman F, Young A, Hoeller C, Hersey P, Dummer R, Khattak MA, Millward M, Patel SP, Haydon A, Johnson DB, Lo S, Blank CU, Sandhu S, Carlino MS, Larkin JMG, Menzies AM, Long GV

(2020), Ann Oncol, 31(8), 1075-82

DOI: 10.1016/j.annonc.2020.04.471

Treatment of High Risk Resected Melanoma in Australia: Current Landscape and Practises

Bhave P, Haydon A

(2020), Australas J Dermatol, 61(3), 203-9

DOI: 10.1111/ajd.13309

Caution in the age of optimism; a salient lesson in advanced melanoma

Roberts HN, Haydon A

(2020), Ann Transl Med, 8(11), 720

DOI: 10.21037/atm.2020.01.125

Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma

Dummer R, Hauschild A, Santinami M, Atkinson V, Mandalà M, Kirkwood JM, Chiarion Sileni V, Larkin J, Nyakas M, Dutriaux C, Haydon A, Robert C, Mortier L, Schachter J, Lesimple T, Plummer R, Dasgupta K, Gasal E, Tan M, Long GV, Schadendorf D

(2020), NEW ENGL J MED, 383(12), 1139-48

DOI: 10.1056/NEJMoa2005493

Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial

Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson VG, Dalle S, Haydon AM, Meshcheryakov A, Khattak A, Carlino MS, Sandhu S, Larkin J, Puig S, Ascierto PA, Rutkowski P, Schadendorf D, Koornstra R, Hernandez-Aya L, Di Giacomo AM, van den Eertwegh AJM, Grob JJ, Gutzmer R, Jamal R, Lorigan PC, van Akkooi ACJ, Krepler C, Ibrahim N, Marreaud S, Kicinski M, Suciu S, Robert C

(2020), J Clin Oncol, 38(33), 3925-36

DOI: 10.1200/JCO.20.02110

Eftilagimod alpha, a soluble lymphocyte activation gene-3 (LAG-3) protein plus pembrolizumab in patients with metastatic melanoma

Atkinson V, Khattak A, Haydon A, Eastgate M, Roy A, Prithviraj P, Mueller C, Brignone C, Triebel F

(2020), J Immunother Cancer, 8(2), e001681

DOI: 10.1136/jitc-2020-001681

A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia

Lickliter JD, Gan HK, Voskoboynik M, Arulananda S, Gao B, Nagrial A, Grimison P, Harrison M, Zou J, Zhang L, Luo S, Lahn M, Kallender H, Mannucci A, Somma C, Woods K, Behren A, Fernandez-Penas P, Millward M, Meniawy T

(2020), DRUG DES DEV THER, 14, 1177-89

DOI: 10.2147/DDDT.S243787

Stereotactic Radiation Therapy Combined With Immunotherapy Against Metastatic Melanoma: Long-Term Results of a Phase 1 Clinical Trial

Ratnayake G, Reinwald S, Shackleton M, Moore M, Voskoboynik M, Ruben J, van Zelm MC, Yu D, Ward R, Smith R, Haydon A, Senthi S

(2020), INT J RADIAT ONCOL, 108(1), 150-6

DOI: 10.1016/j.ijrobp.2020.05.022

First-in-human phase 1 study of MK-1248, an anti-glucocorticoid-induced tumor necrosis factor receptor agonist monoclonal antibody, as monotherapy or with pembrolizumab in patients with advanced solid tumors

Geva R, Voskoboynik M, Dobrenkov K, Mayawala K, Gwo J, Wnek R, Chartash E, Long GV

(2020), CANCER-AM CANCER SOC, 126(22), 4926-35

DOI: 10.1002/cncr.33133

Combination of BRAF and MEK inhibition in BRAF V600E mutant low-grade ganglioglioma

Yau WH, Ameratunga M

(2020), J Clin Pharm Ther, 45(5), 1172-4

DOI: 10.1111/jcpt.13112

Radiological Patterns of Drug-induced Interstitial Lung Disease (DILD) in Early-phase Oncology Clinical Trials

Terbuch A, Tiu C, Candilejo IM, Scaranti M, Curcean A, Bar D, Estevez Timon M, Ameratunga M, Ang JE, Ratoff J, Minchom AR, Banerji U, de Bono JS, Tunariu N, Lopez JS

(2020), Clin Cancer Res, 26(18), 4805-13

DOI: 10.1158/1078-0432.CCR-20-0454